Thus, it may be worth to re-evaluate clinical practice in the light of novel findings, in order to understand what would be the best strategy to follow-up BC patients, especially if treated with anti-HER2 therapy, prior, during and after anticancer treatment. This evidence concerns the gene ERBB2 and breast cancer.